Fulvestrant

CLINICAL USE

Treatment of post-menopausal women with oestrogen-receptor-positive, locally advanced or metastatic breast cancer

DOSE IN NORMAL RENAL FUNCTION

250 mg monthly

PHARMACOKINETICS

  • Molecular weight                           :606.8
  • %Protein binding                           :99
  • %Excreted unchanged in urine     : <1
  • Volume of distribution (L/kg)       :3–5
  • half-life – normal/ESRD (hrs)      :40 days/unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   :Unlikely to be dialysed. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    IM

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    As it is an intramuscular injection, use with caution in patients who are heparinised.

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia